• Restoring the blood-brain barrier?

    From ScienceDaily@1:317/3 to All on Tuesday, June 20, 2023 22:30:28
    Restoring the blood-brain barrier?

    Date:
    June 20, 2023
    Source:
    Stanford Medicine
    Summary:
    Scientists discover a treatment in mice to repair the blood-brain
    barrier, which is key to brain health.


    Facebook Twitter Pinterest LinkedIN Email

    ==========================================================================
    FULL STORY ========================================================================== There's a bouncer in everyone: The blood-brain barrier, a layer of
    cells between blood vessels and the rest of the brain, kicks out toxins, pathogens and other undesirables that can sabotage the brain's precious
    gray matter.

    When the bouncer is off its guard and a rowdy element gains entry,
    a variety of conditions can crop up. Barrier-invading cancer cells can
    develop into tumors, and multiple sclerosis can occur when too many white
    blood cells slip pass the barrier, leading to an autoimmune attack on
    the protective layer of brain nerves, hindering their communication with
    the rest of the body.

    "A leaky blood-brain barrier is a common pathway for a lot of brain
    diseases, so to be able to seal off the barrier has been a long
    sought-after goal in medicine," said Calvin Kuo, MD, PhD, the Maureen
    Lyles D'Ambrogio Professor and a professor of hematology.

    Methods of repairing the blood-brain barrier remain understudied,
    according to Kuo. But a recent paper he and colleagues led describes a treatment that could be instrumental in restoring the barrier's normal function. Kuo is the senior author of the paper, published in Nature Communications on June 2.

    "We have evaluated a new therapeutic class of molecules that can be
    used to treat a leaky blood-brain barrier; previously, there were no
    treatments directed at the blood-brain barrier specifically," Kuo said.

    The researchers started their quest by looking at WNT signaling, a communication pathway used by cells to promote tissue regeneration and
    wound healing. WNT signaling helps maintain the blood-brain barrier by promoting cell-to-cell communication that lines brain blood vessels.

    "There's a lot of historical data that indicated that the WNT signaling
    pathway would be important for maintaining the blood-brain barrier,"
    Kuo said. "The opportunity arose to test a novel WNT signaling pathway
    that would turn on signaling in the blood-brain barrier by binding
    very selectively to a receptor called frizzled." Scientists have been
    focusing on frizzled, a protein receptor that initiates the WNT pathway,
    for blood-brain barrier therapies since mouse mutations in the frizzled
    gene cause blood-brain barrier abnormalities.

    How it's made Many different molecules bind to frizzled protein receptors,
    so to narrow their search for a potential therapeutic molecule, the
    researchers selected only those that specifically target cells that line
    the brain's blood vessels.

    Chris Garcia, PhD, a professor of molecular and cellular physiology as
    well as the Younger Family Professor, developed prototype therapeutic
    WNT pathway molecules in the lab, including a molecule that activates
    the frizzled receptor FZD4. Building off of the work of Garcia and Kuo, collaborators at a research company created L6-F4-2, a FZD4 binding
    molecule that activates WNT signaling 100 times more efficiently than
    other FZD4 binders.

    When the team, including Jie Ding, a research scientist and the lead
    author of the paper, activated WNT signaling at a higher rate, they saw
    an increase in blood-brain barrier strength.

    Keeping the bouncer on duty The researchers wanted to study what happens
    when the natural molecular key for frizzled is missing, and whether it
    can be replaced successfully with L6-F4-2.

    So they turned to Norrie disease, a genetic abnormality that results in
    a leaky blood-retinal barrier.

    The blood-retinal barrier performs the same function for the eye as
    the blood- brain barrier does for the brain. In Norrie disease, the
    development of blood vessels of the retina -- the layer of light-sensitive cells in the back of the eye -- is hindered, resulting in leaky blood
    vessel connections, improper development and blindness.

    Norrie disease results from mutations in the NDP gene, which provides instructions for making a protein called Norrin, which is the key that
    fits the lock of the FZD4receptor and turns it on. In the study's mice,
    the gene is inactivated, and the key is missing causing a leaky barrier
    and blindness. The scientists replaced the missing Norrin protein with
    L6-F4-2, which they call a surrogate.

    When L6-F4-2 replaced the missing Norrin protein, the blood-retinal
    layer was restored in the mice. Researchers knew this because they
    imaged the blood vessels and found them to be denser, and less leaky,
    than before treatment.

    Scientists also showed that, for the blood-brain barrier surrounding
    the mice cerebellum -- a region responsible for muscle coordination --
    L6-F4-2 replaced Norrin and activated WNT signaling.

    Next, the researchers wanted to study a more common human condition --
    ischemic stroke (in which blood vessels and the blood-brain barrier are damaged, and fluid, blood and inflammatory proteins involved in cellular communication can leak into the brain. They found that L6-F4-2 reduced
    the severity of stroke and improved survival of mice compared with mice
    that had untreated strokes.

    Importantly, L6-F4-2 reversed the leakiness of brain blood vessels
    after stroke. Mice treated with L6-F4-2 had increased stroke survival,
    compared to those that were not treated.

    The finding shows that, in mice, the blood-brain barrier could be restored
    by drugs that activate FZD receptors and the WNT signaling pathway.

    Because a variety of disorders have their origin in blood-brain barrier dysfunction, Kuo is excited about the treatment potential for a variety
    of other neurological diseases, such as Alzheimer's, multiple sclerosis
    and brain tumors.

    "We hope this will be a first step toward developing a new generation
    of drugs that can repair the blood-brain barrier, using a very different strategy and molecular target than current medications," Kuo said.

    * RELATED_TOPICS
    o Health_&_Medicine
    # Brain_Tumor # Hypertension # Blood_Clots # Anemia
    o Mind_&_Brain
    # Brain_Injury # Brain-Computer_Interfaces #
    Disorders_and_Syndromes # Neuroscience
    * RELATED_TERMS
    o Stroke o Peripheral_nervous_system o Cerebral_contusion
    o Brain_damage o West_Nile_virus o Brain_tumor o
    Deep_brain_stimulation o Amygdala

    ========================================================================== Story Source: Materials provided by Stanford_Medicine. Original written
    by Emily Moskal.

    Note: Content may be edited for style and length.


    ========================================================================== Journal Reference:
    1. Jie Ding, Sung-Jin Lee, Lukas Vlahos, Kanako Yuki, Cara C. Rada,
    Vincent
    van Unen, Meghah Vuppalapaty, Hui Chen, Asmiti Sura, Aaron
    K. McCormick, Madeline Tomaske, Samira Alwahabi, Huy Nguyen, William
    Nowatzke, Lily Kim, Lisa Kelly, Douglas Vollrath, Andrea Califano,
    Wen-Chen Yeh, Yang Li, Calvin J. Kuo. Therapeutic blood-brain
    barrier modulation and stroke treatment by a bioengineered
    FZD4-selective WNT surrogate in mice. Nature Communications, 2023;
    14 (1) DOI: 10.1038/s41467-023-37689-1 ==========================================================================

    Link to news story: https://www.sciencedaily.com/releases/2023/06/230620113821.htm

    --- up 1 year, 16 weeks, 1 day, 10 hours, 50 minutes
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)